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Introduction
Cardiac surgery has progressed over five decades from a rather 
experimental period to highly standardized procedures with 
very limited mortality. This is especially true for coronary 
artery bypass grafts (CABG) for which mortality is currently 
often reported to be below 2.0% (1,2), despite progressive 
increase in patients’ age and complexity. This has been made 
possible by general improvement in surgical and perioperative 
management but also by technical progresses, especially 
regarding the extra-corporeal circuit (ECC). Obviously, 
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30 days was 0.9%.
Conclusions: Cardioplexol™ seems very promising. It appears especially efficient and safe when used for 
CABG procedures performed with a MiECC.
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cardioplegia also allowed a critical step in the history of cardiac 
surgery. This especially in the 70’s with the almost parallel 
apparition of the still well established Bretschneider Custodiol 
solution, the St-Thomas Plegisol solution as well as the 
Buckberg blood cardioplegia concept. Interestingly however, 
only very few cardioplegic solutions are registered as medical 
product (drug) and have a market authorization. In fact, a 
majority of hospitals still prepares their own cardioplegic 
solutions or outsources this production to external providers. 
Also, most cardiac surgeons and/or perfusionists supplement 
the solution by additional doses of electrolytes or other 
chemicals according to individual believes. Indeed, several 
surveys have shown that myocardial protection strategies 
largely vary from one center to the other or even from one 
surgeon to the other (3-5). It is therefore very difficult to 
obtain a clear overview of current practice, and even more 
difficult to reliably compare the real efficacy and safety of these 
individual preparations. It appears thus that there is still today 
no consensus regarding the optimal cardioplegic solution (6).
Cardioplexol™ was initially conceived as a solution 
adapted for the emerging concept of less invasive ECC, 
the so-called mini-ECC or MiECC, a low-priming 
closed circuit operating at constant volume and which 
is considered less invasive than standard ECC (7-10). 
The objective was to obtain a solution that followed the 
same chemical principles as other standard procedures 
but that also allowed for a much faster administration, a 
critically reduced volume, a longer delay before second 
administration, and mostly the induction of an almost 
immediate cardiac arrest. Cardioplexol™ was introduced in 
our surgical activity initially as a previous version in 2003, 
then since September 1st, 2008 as the currently used form.
In the present paper, we present the results or our single 
center experience with Cardioplexol™ when used with 
MiECC for isolated CABG.
Methods
Design
The current study is a single centre, retrospective analysis of 
consecutive isolated CABG procedures performed between 
September 1st, 2008 and December 31st, 2014.
Cardioplexol™
Cardioplexol™ (ongoing registration process in selected EU 
countries) is produced for our Clinic by the Laboratorium 
Dr. G. Bichsel AG (Unterseen, Switzerland). Cardioplexol™ 
is composed of potassium, magnesium and xylitol (solution 
A, 95 mL) and procaine (solution B, 5 mL) and comes in 
a small card box that can be stored at room temperature. 
Boxes must be placed at least 3–4 hours before use so that the 
solutions can reach a temperature of 2–8 ℃. Shortly before 
administration, solutions A and B are mixed (total =100 mL) 
and distributed in two 50 mL syringes ready to be injected. 
Surgical technique and Cardioplexol™ administration
Surgical procedures are standardized and performed via 
a full sternotomy using a MiECC system. A standard 
cardioplegic cannula is placed in the aortic root and flushed 
before the first 50 mL Cardioplexol™ syringe is connected 
via a 3-way stop cock. The bypass is initiated, the aorta is 
cross-clamped and the content of the first Cardioplexol™ 
syringe is injected without delay, immediately followed by 
the content of the second syringe. The complete injection 
of the 100 mL Cardioplexol™ typically lasts less than 
10 seconds and the heart usually stops beating already after 
a few seconds. The surgeon can immediately proceed with 
the coronary procedures. 
Need for a second, third and fourth Cardioplexol™ 
administration
The initial dose of 100 mL is typically sufficient for the first 
45–60 minutes of ischemia. After a cross-clamp period of 
45 minutes and in case the surgeon foresees a prolongation 
of the ischemic time over 60 minutes, a second dose of 
50–100 mL Cardioplexol™ (depending on the estimated 
remaining ischemic period) must be administered. After 
a cross-clamp period of 75 minutes and in case the 
surgeon foresees a prolongation of the ischemic time over 
90 minutes, a third dose of 50–100 mL (depending on the 
estimated remaining ischemic period) must be administered. 
After a cross-clamp period of 105 minutes and in case the 
surgeon foresees a prolongation of the ischemic time over 
120 minutes, a fourth dose of 50–100 mL (depending on the 
estimated remaining ischemic period) must be administered. 
Data collection, follow-up, and definitions
All consecutive patients, between September 1st, 2008 and 
December 31st, 2014, who underwent a CABG procedure 
with a MiECC, were considered in the current analysis. All 
relevant pre-, peri-, and post-operative data (up to day 30) 
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were retrieved from our prospectively updated and 
independently managed surgery registry (Dendrite, Dendrite 
Clinical Systems Ltd, Oxfordshire, UK). Each patient was 
individually contacted 1 year after surgery for follow-up 
purposes. Alternatively or for complementary information, 
the GP or cardiologist may have been contacted as well. The 
cantonal ethics committee approved the current analysis 
as part of our regularly performed quality control, and all 
patients provided informed consent regarding inclusion of 
their pseudonymised data in this analysis.
Tr o p o n i n  T  a n d  C K - M B  w e r e  a s s e s s e d  b y 
electrochemiluminescence using an immunoassay on a 
Modular analytics E170 platform (Roche Diagnostics, 
Mannheim, Germany). The identification of perioperative 
myocardial infarction (MI) was based on the Third Universal 
Definition of Myocardial Infarction and on the criteria used 
in the SYNTAX trial as previously described (11). In brief, 
a MI was assumed if 2 or more of the 3 following criteria 
were present within the first 7 days following CABG: (I) 
new Q-wave or new left bundle-branch block compared to 
the pre-operative echocardiography (ECG); (II) creatine 
kinase-MB (CK-MB) >60 mg/L; (III) Post-operative severe 
wall motion abnormalities in ECG corresponding with 
ischemic ECG changes or angiographically documented 
new graft or native coronary artery occlusion or myocardial 
necrosis diagnosed by autopsy. Electrocardiograms (ECG) 
were all independently evaluated by a senior physician and a 
cardiologist. Post-operative echocardiography was performed 
by a physician independent of the current study and only 
if clinically indicated. A diagnosis of post-operative stroke 
was retained in case of neurological dysfunction related to 
confirmed focal cerebral infarction. Post-operative new-onset 
renal insufficiency was defined by a new need for dialysis or, 
in patients with pre-operative creatinine levels below 2 mg/dL 
(172 μmol/L), if the post-operative creatinine level rose 
above 2 mg/dL and reached at least double the pre-operative 
value during hospitalisation.
Statistics
Results regarding continuous variables are expressed as 
mean ± standard deviation (SD) and median with quartile 
range and minimum/maximum values. Categorical variables 
are presented as absolute numbers and percentages.
Results
Out of a total of 7,447 adult cardiac surgical operations 
performed during the 76 months observational period, 
2,416 were isolated CABG procedures. Patients were 
66.2±9.7 years old, 81.3% were males and the median 
logistic EuroSCORE was 3.2. Further patients’ baseline 
characteristics are summarized in Table 1. 
Patients had a coronary artery disease affecting in average 
2.8±0.5 vessels, the left main artery being involved in 25.5% 
of the cases. Further operative data are presented in Table 2. 
In average, 3.2 vessels were bypassed. The median value 
cross-clamp time was 45 minutes and more than 75% of 
the procedures could be performed with a cross-clamp time 
of less than 60 minutes. The volume of Cardioplexol™ 
administered during a procedure was in average 111±32 mL 
with more than 75% of the cases who received only one 
dose of 100 mL. Blood potassium assessed 5 minutes after 
Cardioplexol™ injection was 4.4±0.5 mEq/L. Hematocrit 
during the procedure was 28.5%±4.8%. After reperfusion, 
the heart recovered a spontaneous rhythmic activity and 
necessitated an internal electrical cardioversion in only 9.5% 
of the cases (Table 2).
Maximal value of troponin T during the first hours 
following myocardial reperfusion was 0.9±4.5 ng/mL 
(median =0.4 ng/mL) with an overall profile of average values 
around 0.6±1.4 ng/mL between 6 and 24 hours (Table 3). 
Maximal CK-MB value was 29.6±60.6 U/L (Table 3).
ICU stay was in average 1.4±2.3 days (median: 1 day) and 
was less than 48 hours for 86.3% of the patients (Table 4). 
Post-operative hospitalization stay was 9.7±8.4 days with a 
median of 8 days (Table 4).
Post-operative complications are summarized in Table 5. 
A post-operative MI was diagnosed in 3.3% of the patients. 
A stroke was confirmed in 2.3% of the patients. A new renal 
insufficiency appeared in 2.1% of the patients and 0.7% 
of the patients necessitated a dialysis (Table 5). Hospital 
mortality and 30 days mortality were 0.9% and 1.4% 
respectively. At one year, it was 4.7% (Table 6).
Discussion
Myocardial protection has always been a matter of extended 
research. After initial controversial results in the 50–60’s, 
it is eventually in the 70’s, that a few cardioplegic solutions 
became accepted as reliable means to arrest and protect 
the myocardium during prolonged periods of aortic cross-
clamping. This allowed further development and wide 
spreading of cardiac surgical activity on the one hand 
and the performance of increasingly complex operations. 
Interestingly, since then, only minor improvements have 
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Table 1 Baseline patients’ demographics and risk factors
Variable N Mean ± SD (95% CI) or n (%) Median [Min, lqr, uqr, Max]
Demographics
Age 2,416 66.2±9.7 (65.8 to 66.6) 67.0 [30, 60, 74, 90]
Male 2,416 1,963 (81.3) –
BMI 2,416 27.8±4.6 (27.7 to 28.0) 27.4 [9, 25, 30, 61]
Risk factors
Tobacco 2,308 1,424 (61.7) –
Dyslipidemia 2,361 1,974 (83.6) –
Hypertension 2,409 1,973 (81.9) –
Urgency/emergency 2,416 677 (28.0) –
Redo 2,416 29 (1.2) –
Logistic EuroSCORE 2,416 6.5±9.4 (6.1 to 6.9) 3.2 [1, 2, 7, 92]
Ejection fraction (%) 2,416 55.6±13.0 (55.1 to 56.1) 60.0 [10, 50, 65, 88]
Ejection fraction (<35%) 2,416 175 (7.2) –
Ejection fraction (≥35% to 50%) 2,416 404 (16.7) –
Ejection fraction (≥50%) 2,416 1,837 (76.0) –
Creatinine pre-op (mg/dL) 2,416 89.7±55.4 (87.5 to 91.9) 80.0 [38, 70, 93, 835]
Renal insufficiency 2,414 316 (13.2) –
NYHA classification
NYHA 1 2,416 1,005 (41.6) –
NYHA 2 2,416 863 (35.7) –
NYHA 3 2,416 442 (18.3) –
NYHA 4 2,416 106 (4.4) –
N, number of patients with available data; SD, standard deviation; CI, confidential interval; Min, minimal value; lqr, lower quartile; uqr, 
upper quartile; Max, maximal value; BMI, Body mass index; NYHA, New York Heart Association.
been brought into the cardioplegic field and still today, 
most procedures are performed with solutions based on the 
Bretschneider, St-Thomas or Buckberg principles. The idea 
of developing a new cardioplegic solution at our institution 
was initially a consequence of our early interest for mini 
heart lung machines (12). It was indeed thought that a large 
volume of cardioplegia would be in contradiction with 
the basic low-volume advantage of MiECC systems. Our 
objectives became then to develop an ultra low-volume 
cardioplegia, which effect would be prolonged and that 
could be administered by the surgeon him/herself. After 
initial versions fabricated by our hospital pharmacy, the 
development toward a marketable solution necessitated 
further investments and collaboration with professional 
companies. A start-up company was created in order to 
support this development.
The current Cardioplexol™ solution has been used 
in our clinic since September 2008. It has immediately 
confirmed several attractive surgical advantages such as the 
limited manipulations required for its preparation, the direct 
and rapid administration by the surgeon him/herself and as 
consequence, the elimination of the cardioplegia set. But the 
most appreciated advantages were certainly the immediate 
cardiac arrest (within a few seconds) and the prolonged 
delay before a second or further administrations are needed 
(45 minutes). Overall, these two aspects allow a remarkable 
reduction of the cross-clamp time, i.e., a limitation of the 
ischemic period. In a recently performed pivotal phase 3 
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Table 2 Procedural data
Variable N Mean ± SD (95% CI) or n (%) Median [Min, lqr, uqr, Max]
Procedure
Coronary artery disease 2,416 2.8±0.5 (2.8 to 2.8) 3.0 [0, 3, 3, 3]
Left main artery 2,416 615 (25.5) –
Distal anastomoses 2,416 3.2±0.8 (3.2 to 3.3) 3.0 [1, 3, 4, 6]
Combination with other minor procedures* 2,416 148 (6.1) –
Cardio-technic
Machine balance (mL) 2,411 640±579 (616 to 663) 600.0 [−1510, 240, 1,008, 4,289]
Volume (mL) 1,926 1,662±658 (1,636 to 1,688) 1,600.0 [0, 1,200, 2,000, 6,400]
UF 2,416 0 (0.0) –
Cardioplexol™ volume (mL) 1,180 111±32 (109 to 112) 100 [50, 100, 100, 604]
K+ 1,167 4.4±0.5 (4.4 to 4.4) 4.4 [3, 4, 5, 8]
Ht (%) 1,163 28.5±4.8 (28.3 to 28.7) 28.0 [15, 25, 32, 41]
pH 1,166 7.4±0.0 (7.4 to 7.4) 7.4 [7, 7, 7, 8] 
Surgery
Duration of operation (min) 2,416 212.9±47.8 (211.0 to 214.8) 210.0 [32, 180, 240, 815]
ECC time (min) 2,412 75.0±24.2 (74.1 to 76.0) 72.0 [11, 59, 89, 243]
Cross-clamp time (min) 2,411 47.1±16.1 (46.4 to 47.7) 45.0 [3, 36, 56, 139]
Reperfusion time (min) 2,402 25.3±10.9 (24.8 to 25.7) 24.0 [3, 18, 30, 167]
Defibrillation 
Number of patients 2,409 230 (9.5) –
External defibrillation 2,409 0 (0.0) –
Number of repetition 223 1.3±0.8 (1.2 to 1.3) 1.0 [1, 1, 1, 10]
Joules 220 29.8±31.2 (28.6 to 31.1) 20.0 [10, 20, 30, 440]
*, details of the combination are: ablation [20], closure of patent foramen ovale [93], intra aortic balloon pump [52], left atrial appendage 
closure [51] or other [13]. N, number of patients with available data. SD, standard deviation; CI, confidential interval; Min, minimal value; 
lqr, lower quartile; uqr, upper quartile; Max, maximal value. UF, ultrafiltration. K+, blood potassium level 5 minutes after Cardioplexol™ 
injection (mEq/L). Ht, hematocrite. 
randomized study comparing Cardioplexol™ and Buckberg, 
the cross-clamp time appeared reduced by approximately 
10 minutes (data not yet published, results partially available 
under www.clinicaltrialsregister.eu). 
The aim of the current paper was to introduce the 
Cardioplexol™ solution and present for the first time 
the results of the initial clinical experience with a large 
collective of patients. Although it was not the intention of 
this paper to demonstrate significant clinical advantage of 
Cardioplexol™ as compared to well-established reference 
solutions, our data can still be used to challenge those found 
in the literature, especially since the profile of our patients 
corresponds to the one of patients operated in most western 
clinics and to those reported in most publications.
TnT although always elevated after a cardiac operation, 
is today considered as an adequate surrogate to evaluate 
the quality of intra-operative myocardial protection. The 
degree of post-operative TnT elevation is also recognized 
as a prognostic marker of early-, mid- and long-term 
mortality (2,11,13-18). In our current experience, median 
values of TnT at around 6, 12 and 24 hours post myocardial 
reperfusion were around 0.3 ng/mL and the median of 
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Table 3 “24-hour” post-operative evolution of cardiac enzymes
Variable N Mean ± SD (95% CI) Median [Min, lqr, uqr, Max]
TnT max (ng/mL) 2,415 0.9±4.5 (0.7 to 1.1) 0.4 [0, 0, 1, 201]
6 hours post surgery1 1,547 0.6±1.4 (0.6 to 0.7) 0.3 [0, 0, 1, 30]
12 hours post surgery1 1,860 0.7±1.4 (0.6 to 0.7) 0.3 [0, 0, 1, 34]
24 hours post surgery1 1,641 0.6±1.4 (0.6 to 0.7) 0.3 [0, 0, 1, 27]
CK max (U/L) 2,415 881±1605 (817 to 945) 542 [58, 360, 894, 52,998]
CK-MB max (U/L) 2,415 29.6±60.6 (27.2 to 32.0) 13.6 [0, 10, 25, 1,527]
1, the range of the 6 hours assessment of TnT and CK-MB extends from 0 to <9 hours post myocardial reperfusion, the range of the  
12 hours assessment extends from 9 to <18 hours post myocardial reperfusion, the range of the 24 hours assessment extends from  
18 to <36 hours post myocardial reperfusion. N, number of patients with available data; SD, standard deviation; CI, confidential interval; 
Min, minimal value; lqr, lower quartile; uqr, upper quartile; Max, maximal value; TnT, troponin T. 
Table 4 ICU and hospitalisation stay
Variable N Mean ± SD (95% CI) or n (%) Median [Min, lqr, uqr, Max]
ICU stay (days) 2,413 1.4±2.3 (1.3 to 1.5) 1.0 [0, 1, 1, 69]
Prolonged ICU stay (>48 hours) 2,416 331 (13.7) –
Hospital stay (days) 2,416 9.7±8.4 (9.4 to 10.0) 8.0 [0, 7, 10, 249]
N, number of patients with available data; SD, standard deviation; CI, confidential interval; Min, minimal value; lqr, lower quartile; uqr, 
upper quartile; Max, maximal value; ICU, intensive care unit.
Table 5 Post-operative complications
Variable N Mean ± SD (95% CI) or n (%) Median [Min, lqr, uqr, Max]
Complications: local
Bleeding 2,409 38 (1.6) –
Infection 2,416 88 (3.6) –
Complications: cardiac
Post-operative myocardial infarct1 2,396 79 (3.3) –
Definitive pace maker 2,390 12 (0.5) –
Resuscitation 2,391 22 (0.9) –
Atrial fibrillation 2,393 458 (19.1) –
Complications: neuro
Stroke 2,416 55 (2.3) –
Complications: renal
Post-operative creatinine (mg/dL) 2,227 93.3±55.1 (91.1 to 95.5) 80.0 [34, 68, 98, 796]
New post-op renal insufficiency2 2,416 51 (2.1) –
New dialysis 2,416 17 (0.7) –
Complications: other
ARDS 2,391 16 (0.7) –
Multiple organ failure 2,389 6 (0.3) –
1,2, see text for definition. N, number of patients with available data; SD, standard deviation; CI, confidential interval; Min, minimal value; 
lqr, lower quartile; uqr, upper quartile; Max, maximal value.
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the maximal value reached during these first 24 hours was 
0.4 ng/mL. These results compare very well with those found 
in the literature (2,14,19-23). The rate of post-operative 
MI (3.3%) is in agreement with the range of 1.4–9.7% that 
can be found in the literature (2,13,20,22-24). Similarly, the 
post-operative stroke incidence of 2.3% also falls within 
the range of 1.6–2.5% reported by others (1,2,25-28). A 
new dialysis was necessary in 0.7% of the patients, which 
is very low as compared to values of 1.4–3.2% found in 
the literature (2,25,26). Finally, the 30 days mortality of 
1.4% compares very favorably with the range of 0.9–4.6% 
reported by others (1,2,25-28).
It appears thus, that besides the advantages mentioned 
earlier in terms of handling and efficiency, Cardioplexol™ 
is also reliable in terms of post-operative morbidity and 
mortality. During the extended period of observation, no 
adverse event could be directly related to the use of this new 
cardioplegic solution. Cardioplegia with Cardioplexol™ 
is thus an attractive alternative solution, especially for 
MiECC procedures. Its use, although very simple, requires 
however a few words of caution. “Traditional” solutions 
with which surgeons have been used to work for years 
require a prolonged coronary perfusion of a high volume as 
well as re-injections every 20–30 minutes. Quite oppositely, 
the Cardioplexol™ solution is restricted to a single bolus 
injection of only 100 mL. With this in mind, it appears 
obvious that the solution must be administered perfectly. 
For this, it is important before the operation, to check the 
competence of the aortic valve since an aortic insufficiency 
would preclude the correct perfusion of the coronary 
arteries. The presence of a ventricular hypertrophy must 
also be checked as a higher initial dose may then provide a 
better protection. 
The current study has certainly limitations including 
its already discussed retrospective and non-comparative 
design. Parts of these results have however served as a basis 
to design a single-center prospective randomized pivotal 
phase 3 study comparing Cardioplexol™ to Buckberg 
blood cardioplegia. Results are not yet published but data 
are partially available under www.clinicaltrialsregister.eu. 
A second phase 3 multicenter study is currently ongoing 
and its design is available under www.clinicaltrials.gov. 
The results of this study are required to complete the 
registration process and eventually get an initial market 
authorization, possibly in 2020–2021 in several European 
countries. 
In conclusion, Cardioplexol™ appears efficient and safe 
for the use in CABG procedures, especially when performed 
with a MiECC system. Its use is however currently limited 
since the product is not yet authorized on the market. 
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